TD Cowen reiterates Buy rating on CVS Health stock, citing limited exposure to individual market risks

TD Cowen has reiterated its Buy rating and $95 price target for CVS Health, asserting that CVS's diversified revenue mix positions it favorably against challenges affecting competitors like Centene. Centene recently withdrew its FY2025 guidance due to a significant $1.8 billion ACA Exchange risk adjustment under-accrual and elevated Medicaid costs, prompting mixed analyst reactions despite stronger performance in its Medicare Advantage and Prescription Drug Plan segments. TD Cowen estimates that comparable issues would have a substantially smaller impact on CVS's adjusted EPS (3.9% vs. Centene's implied 38%), underscoring CVS's strategic resilience, particularly as it plans to exit the Individual & Family Plan market in 2026.

Analysis

TD Cowen's analysis highlights a significant divergence in risk profiles between CVS Health and Centene, rooted in their respective business compositions. Centene's withdrawal of its fiscal year 2025 guidance, driven by a substantial $1.8 billion under-accrual in ACA Health Insurance Exchange risk adjustments and elevated Medicaid costs, has materially impacted its earnings outlook by an estimated $2.75 per share. The firm estimates this vulnerability could hypothetically reduce Centene's adjusted EPS by 38%, as its individual business constitutes approximately 20% of its Health Care Benefits premium revenue. In stark contrast, CVS is positioned more defensively due to its diversified model, where the comparable Individual & Family Plan line represents only 5% of its HCB premium revenue, translating to a much smaller potential EPS impact of just 3.9%. This structural advantage is further compounded by CVS's strategic decision to exit the IFP market in 2026. Furthermore, TD Cowen identifies a potential 1% upside to its 2025 CVS adjusted EPS estimate, stemming from favorable Medicare Advantage and Prescription Drug Plan trends also observed at Centene, reinforcing the Buy rating and $95 price target for CVS.

Key Decisions for Investors

• Investors may consider the relative value between CVS and Centene, as CVS's diversified business model and lower exposure to ACA exchange volatility present a more resilient investment profile compared to the significant uncertainty surrounding Centene.
• For those invested in CVS, the planned exit from the Individual & Family Plan market in 2026 should be viewed as a key de-risking event that validates the positive analyst outlook and reinforces the company's stability.
• Investors holding Centene should closely monitor the company's planned 2026 pricing actions and refiled ACA exchange rates, as these will be critical indicators of management's ability to mitigate the aformentioned risk-adjustment and cost trend issues.